HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · IEX Real-Time Price · USD
0.893
+0.087 (10.82%)
At close: Apr 26, 2024, 4:00 PM
0.891
-0.002 (-0.25%)
After-hours: Apr 26, 2024, 7:59 PM EDT
HOOKIPA Pharma Revenue
In the year 2023, HOOKIPA Pharma had annual revenue of $20.13M with 41.27% growth. Revenue in the quarter ending December 31, 2023 was $7.41M, a -5.38% decrease year-over-year.
Revenue (ttm)
$20.13M
Revenue Growth
+41.27%
P/S Ratio
4.28
Revenue / Employee
$133,305
Employees
151
Market Cap
86.25M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 20.13M | 5.88M | 41.27% |
| Dec 31, 2022 | 14.25M | -4.20M | -22.76% |
| Dec 31, 2021 | 18.45M | -1.14M | -5.80% |
| Dec 31, 2020 | 19.58M | 7.64M | 63.99% |
| Dec 31, 2019 | 11.94M | 4.31M | 56.53% |
| Dec 31, 2018 | 7.63M | - | - |
| Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 111, Inc. | 2.11B |
| The Oncology Institute | 324.24M |
| PetMed Express | 276.97M |
| Burning Rock Biotech | 75.80M |
| Eton Pharmaceuticals | 32.64M |
| Aclaris Therapeutics | 31.25M |
| Gritstone bio | 16.34M |
| Curis | 10.02M |
HOOK News
- 2 days ago - HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab - GlobeNewsWire
- 3 days ago - HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers - GlobeNewsWire
- 10 days ago - HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration - GlobeNewsWire
- 5 weeks ago - HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization - GlobeNewsWire